274 related articles for article (PubMed ID: 33826820)
1. Sutimlimab in Cold Agglutinin Disease.
Röth A; Barcellini W; D'Sa S; Miyakawa Y; Broome CM; Michel M; Kuter DJ; Jilma B; Tvedt THA; Fruebis J; Jiang X; Lin S; Reuter C; Morales-Arias J; Hobbs W; Berentsen S
N Engl J Med; 2021 Apr; 384(14):1323-1334. PubMed ID: 33826820
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of complement C1s improves severe hemolytic anemia in cold agglutinin disease: a first-in-human trial.
Jäger U; D'Sa S; Schörgenhofer C; Bartko J; Derhaschnig U; Sillaber C; Jilma-Stohlawetz P; Fillitz M; Schenk T; Patou G; Panicker S; Parry GC; Gilbert JC; Jilma B
Blood; 2019 Feb; 133(9):893-901. PubMed ID: 30559259
[TBL] [Abstract][Full Text] [Related]
3. Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial.
Röth A; Berentsen S; Barcellini W; D'Sa S; Jilma B; Michel M; Weitz IC; Yamaguchi M; Nishimura JI; Vos JMI; Storek M; Wong N; Patel P; Jiang X; Vagge DS; Wardęcki M; Shafer F; Lee M; Broome CM
Blood; 2022 Sep; 140(9):980-991. PubMed ID: 35687757
[TBL] [Abstract][Full Text] [Related]
4. Sustained inhibition of complement C1s with sutimlimab over 2 years in patients with cold agglutinin disease.
Röth A; Barcellini W; D'Sa S; Miyakawa Y; Broome CM; Michel M; Kuter DJ; Jilma B; Tvedt THA; Weitz IC; Yoo R; Jayawardene D; Vagge DS; Kralova K; Shafer F; Wardȩcki M; Lee M; Berentsen S
Am J Hematol; 2023 Aug; 98(8):1246-1253. PubMed ID: 37246953
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of complement C1s in patients with cold agglutinin disease: lessons learned from a named patient program.
Gelbenegger G; Schoergenhofer C; Derhaschnig U; Buchtele N; Sillaber C; Fillitz M; Schenk TM; D'Sa S; Cartwright R; Gilbert JC; Jilma B; Jaeger U
Blood Adv; 2020 Mar; 4(6):997-1005. PubMed ID: 32176765
[TBL] [Abstract][Full Text] [Related]
6. Sutimlimab: A Complement C1s Inhibitor for the Management of Cold Agglutinin Disease-Associated Hemolysis.
Moore DC; Arnall JR
Ann Pharmacother; 2023 Aug; 57(8):970-977. PubMed ID: 36476151
[TBL] [Abstract][Full Text] [Related]
7. Sutimlimab: First Approval.
Dhillon S
Drugs; 2022 May; 82(7):817-823. PubMed ID: 35412113
[TBL] [Abstract][Full Text] [Related]
8. Complement-directed therapy for cold agglutinin disease: sutimlimab.
Broome CM
Expert Rev Hematol; 2023; 16(7):479-494. PubMed ID: 37256550
[TBL] [Abstract][Full Text] [Related]
9. Sutimlimab for treatment of cold agglutinin disease: why, how and for whom?
Berentsen S; Barcellini W; D'Sa S; Jilma B
Immunotherapy; 2022 Oct; 14(15):1191-1204. PubMed ID: 35946351
[TBL] [Abstract][Full Text] [Related]
10. Sutimlimab improves quality of life in patients with cold agglutinin disease: results of patient-reported outcomes from the CARDINAL study.
Röth A; Barcellini W; Tvedt THA; Miyakawa Y; Kuter DJ; Su J; Jiang X; Hobbs W; Arias JM; Shafer F; Weitz IC
Ann Hematol; 2022 Oct; 101(10):2169-2177. PubMed ID: 35999387
[TBL] [Abstract][Full Text] [Related]
11. Sutimlimab provides clinically meaningful improvements in patient-reported outcomes in patients with cold agglutinin disease: Results from the randomised, placebo-controlled, Phase 3 CADENZA study.
Röth A; Broome CM; Barcellini W; Jilma B; Hill QA; Cella D; Tvedt THA; Yamaguchi M; Lee M; Shafer F; Wardęcki M; Jiang X; Patel P; Joly F; Weitz IC
Eur J Haematol; 2023 Mar; 110(3):280-288. PubMed ID: 36403132
[TBL] [Abstract][Full Text] [Related]
12. Sutimlimab Pharmacokinetics and Pharmacodynamics in Patients with Cold Agglutinin Disease.
Frank T; Kovar A; Strougo A; Vage C; Teuscher N; Wong N
J Pharmacol Exp Ther; 2023 Aug; 386(2):143-155. PubMed ID: 37164370
[TBL] [Abstract][Full Text] [Related]
13. Safety, tolerability, and activity of the active C1s antibody riliprubart in cold agglutinin disease: a phase 1b study.
D'Sa S; Vos JMI; Barcellini W; Wardęcki M; Perrin L; Barker G; Zilberstein M; Storek M; Chow T; Röth A
Blood; 2024 Feb; 143(8):713-720. PubMed ID: 38085846
[TBL] [Abstract][Full Text] [Related]
14. A Randomized, First-in-Human, Healthy Volunteer Trial of sutimlimab, a Humanized Antibody for the Specific Inhibition of the Classical Complement Pathway.
Bartko J; Schoergenhofer C; Schwameis M; Firbas C; Beliveau M; Chang C; Marier JF; Nix D; Gilbert JC; Panicker S; Jilma B
Clin Pharmacol Ther; 2018 Oct; 104(4):655-663. PubMed ID: 29737533
[TBL] [Abstract][Full Text] [Related]
15. Eculizumab in cold agglutinin disease (DECADE): an open-label, prospective, bicentric, nonrandomized phase 2 trial.
Röth A; Bommer M; Hüttmann A; Herich-Terhürne D; Kuklik N; Rekowski J; Lenz V; Schrezenmeier H; Dührsen U
Blood Adv; 2018 Oct; 2(19):2543-2549. PubMed ID: 30291112
[TBL] [Abstract][Full Text] [Related]
16. Oral Iptacopan Monotherapy in Paroxysmal Nocturnal Hemoglobinuria.
Peffault de Latour R; Röth A; Kulasekararaj AG; Han B; Scheinberg P; Maciejewski JP; Ueda Y; de Castro CM; Di Bona E; Fu R; Zhang L; Griffin M; Langemeijer SMC; Panse J; Schrezenmeier H; Barcellini W; Mauad VAQ; Schafhausen P; Tavitian S; Beggiato E; Chew LP; Gaya A; Huang WH; Jang JH; Kitawaki T; Kutlar A; Notaro R; Pullarkat V; Schubert J; Terriou L; Uchiyama M; Wong Lee Lee L; Yap ES; Sicre de Fontbrune F; Marano L; Alashkar F; Gandhi S; Trikha R; Yang C; Liu H; Kelly RJ; Höchsmann B; Kerloeguen C; Banerjee P; Levitch R; Kumar R; Wang Z; Thorburn C; Maitra S; Li S; Verles A; Dahlke M; Risitano AM
N Engl J Med; 2024 Mar; 390(11):994-1008. PubMed ID: 38477987
[TBL] [Abstract][Full Text] [Related]
17. Long-term sutimlimab improves quality of life for patients with cold agglutinin disease: CARDINAL 2-year follow-up.
Röth A; Broome CM; Barcellini W; Tvedt THA; Miyakawa Y; D'Sa S; Cella D; Bozzi S; Jayawardene D; Yoo R; Shafer F; Wardęcki M; Weitz IC
Blood Adv; 2023 Oct; 7(19):5890-5897. PubMed ID: 37459203
[TBL] [Abstract][Full Text] [Related]
18. Complement C1s inhibition with sutimlimab results in durable response in cold agglutinin disease: CARDINAL study 1-year interim follow-up results.
Roth A; Barcellini W; D'Sa S; Miyakawa Y; Broome CM; Michel M; Kuter DJ; Jilma B; Tvedt THA; Weitz IC; Patel P; Jiang X; Reuter C; Su J; Shafer F; Lee M; Berentsen S
Haematologica; 2022 Jul; 107(7):1698-1702. PubMed ID: 35172561
[No Abstract] [Full Text] [Related]
19. TNT003, an inhibitor of the serine protease C1s, prevents complement activation induced by cold agglutinins.
Shi J; Rose EL; Singh A; Hussain S; Stagliano NE; Parry GC; Panicker S
Blood; 2014 Jun; 123(26):4015-22. PubMed ID: 24695853
[TBL] [Abstract][Full Text] [Related]
20. Sutimlimab suppresses SARS-CoV-2 mRNA vaccine-induced hemolytic crisis in a patient with cold agglutinin disease.
Kobayashi H; Ouchi T; Kitamura W; Asakura S; Yano T; Takeda H; Tokuda Y; Yoshino T; Maeda Y
J Clin Exp Hematop; 2023; 63(4):246-250. PubMed ID: 38148014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
